ACR Convergence 2026

November 6-11, 2026. Orlando, Florida.

View by Number View by Title View Sessions

All • a b c d e f g h i j k l m n o p q r s t u v w x y [z]

Abstract Number: 1643

Zasocitinib, a Highly Selective Once-Daily TYK2 Inhibitor, Demonstrates Consistent Improvements in Quality of Life and PSSD-Reported Itch and All Other Symptoms in Adults with Moderate-to-Severe Plaque Psoriasis: Results From Two Randomized Phase 3 Trials (LATITUDE-PsO-3001 and 3002)

All • a b c d e f g h i j k l m n o p q r s t u v w x y [z]